Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome.

摘要: Most drugs are ineffective for the long-term treatment of irritable bowel syndrome (IBS). The beneficial effects medical IBS poor and last only a relative short time. Over period 6 months, we investigated effectiveness cimetropium bromide, new antimuscarinic compound, in patients with IBS. Forty-eight were treated at random double-blind fashion bromide (50 mg, tid) or placebo months. Personal diary cards monthly check-ups guaranteed monitoring symptoms (mainly pain). In addition, personality patterns (MHQ-CBA tests) obtained before after therapy, both to detect possible psychoneurotic traits observe changes these relation pain symptoms. Three on one dropped out. At end scores had decreased an average 16% group 87% (p less than 0.01). Twenty (87%) versus five (24%) considered themselves be globally improved MHQ test showed significant improvement anxiety score only. CBA confirmed decrease state (STAI-X-1) treatment. Eleven (48%) reported side dry mouth sleepiness), but none withdrew from study. results this trial indicate that significantly improves associated psychological disorders.